• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Cyclophosphamide"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 81

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients with Breast Cancer and One to Nine Infiltrated Nodes: Five-Year Results of the Hellenic Cooperative Oncology Group Randomized HE 10/92 Study 

      Fountzilas, George; Stathopoulos, G. P.; Kouvatseas, G.; Polychronis, A.; Klouvas, G. D.; Samantas, E.; Zamboglou, N.; Kyriakou, K.; Adamou, A.; Pectasides, Dimitrios; Economopoulos, T.; Kalofonos, H. P.; Bafaloukos, Dimitrios; Georgoulias, V.; Razi, E. D.; Koukouras, D.; Zombolas, V.; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas (2004)
      The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, ...

    • Article  

      Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience 

      Pectasides, Dimitrios; Fountzilas, George; Aravantinos, Gerasimos; Kalofonos, H. P.; Efstathiou, E.; Farmakis, D.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Economopoulos, T.; Dimopoulos, M. A. (2006)
      Purpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study ...

    • Article  

      Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: The Hellenic Cooperative Oncology Group experience 

      Pectasides, Dimitrios; Economopoulos, T.; Kouvatseas, G.; Antoniou, A.; Zoumbos, Z.; Aravantinos, Gerasimos; Tsatalas, C.; Halikia, A.; Nikolaides, C.; Kiamouris, Ch; Pappa, E.; Pavlidis, Nicholas; Skarlos, Dimosthenis V.; Fountzilas, George; Dimopoulos, M. A. (2000)
      Testicular non-Hodgkin's lymphoma is an uncommon disease and its outcome following chemotherapy and/or radiotherapy has been variable. A retrospective analysis was performed on 26 patients with primary testicular lymphoma ...

    • Article  

      Cancer and pregnancy: A comprehensive review 

      Voulgaris, E.; Pentheroudakis, George; Pavlidis, Nicholas (2011)
      Background: Pregnancy complicated by cancer is relatively rare but, as women in western societies tend to delay childbearing to the third and fourth decade of life, this phenomenon is going to be encountered more often in ...

    • Article  

      Cancer and pregnancy: Poena magna, not anymore 

      Pentheroudakis, George; Pavlidis, Nicholas (2006)
      Cancer diagnosed during pregnancy constitutes a difficult clinical condition with a devastating impact on the patient's somatic and psychosocial health and possibly on foetal integrity. This circumstance also raises several ...

    • Article  

      Cancer and pregnancy: What should we know about the management with systemic treatment of pregnant women with cancer? 

      Pavlidis, Nicholas (2011)
      The incidence of cancer during pregnancy is a rare phenomenon and is estimated to occur in 1:1000 pregnancies. This co-existence is likely to rise since the delay of childbearing to the later reproductive age is nowadays ...

    • Article  

      Cancer of unknown primary during pregnancy: An exceptionally rare coexistence 

      Pavlidis, Nicholas; Peccatori, Fedro A.; Lofts, F.; Greco, F. A. (2015)
      Background: Cancer in pregnancy is a rare disease with breast cancer, cervical cancer, melanoma and Hodgkin's disease to be the most commonly diagnosed malignancies during gestation. Cancer of unknown primary (CUP) is a ...

    • Article  

      Cancer of unknown primary: Biological and clinical characteristics 

      Pavlidis, Nicholas (2003)

    • Article  

      Cancer, fertility and pregnancy: ESMO Clinical Recommendations for diagnosis, treatment and follow-up 

      Pentheroudakis, George; Pavlidis, Nicholas; Castiglione, M. (2009)

    • Article  

      Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up 

      Pentheroudakis, George; Pavlidis, Nicholas; Castiglione, M. (2008)

    • Article  

      Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study 

      Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Gennatas, Constantinos; Beer, M.; Mylonakis, N.; Makrantonakis, P.; Klouvas, G. D.; Karpathios, S.; Linardou, H.; Konstantaras, C.; Fountzilas, George (1996)
      We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...

    • Article  

      Carcinoma of unknown primary: Natural history and treatment. Analysis of 30 cases and review of the literature 

      Pavlidis, Nicholas; Sourla, A.; Ch, F. Tolis; Theoharis, N. M.; Nikolaou, N. (1990)
      In this study, the natural history and therapeutic management of 30 patients with carcinoma of unknown primary (CUP syndrome) is presented. Despite detailed laboratory investigations, the primary occult tumor was not ...

    • Article  

      CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group 

      Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)
      Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...

    • Article  

      Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support 

      Briassoulis, E. Ch; Froudarakis, M. E.; Milionis, Haralampos J.; Peponis, I. A.; Constantopoulos, S. H.; Pavlidis, Nicholas (2000)
      Several cancer therapeutic agents have been associated with pulmonary toxicity. Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema ...

    • Article  

      Coexistence of pregnancy and malignancy 

      Pavlidis, Nicholas (2002)
      Cancer complicating pregnancy is a rare coexistence. The incidence is approximately 1 in 1,000 pregnancies. The most common cancers are those more frequently seen during the reproductive age of a woman. Breast cancer, ...

    • Article  

      Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A prospective study 

      Tsavaris, N.; Primikirios, N.; Mylonakis, N.; Varouchakis, G.; Dosios, T.; Pavlidis, Nicholas; Skarlos, Dimosthenis V.; Tasopoulos, T.; Dritsas, J.; Kosmidis, Paraskevas A. (1997)
      From June 1984 to October 1995, forty seven consecutive patients (pts) with a confirmed diagnosis of diffuse malignant mesothelioma (MM) of the pleura (41) and peritoneum (6), were treated with cisplatin (CDDP) (24 pts) ...

    • Article  

      Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group 

      Papageorgiou, E.; Tsirigotis, P.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Papageorgiou, S.; Economopoulos, T. (2005)
      To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...

    • Article  

      Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis 

      Golfinopoulos, Vassilis; Pentheroudakis, George; Salanti, G.; Nearchou, A. D.; Ioannidis, J. P. A.; Pavlidis, Nicholas (2009)
      Objectives: To synthesize the evidence from randomized controlled trials concerning systemic treatment regimens for patients with cancer of unknown primary site (CUP). Data sources: PubMed and the Cochrane Library Central ...

    • Article  

      Cutaneous lymphocytic vasculopathy in lymphoproliferative disorders-a paraneoplastic lymphocytic vasculitis of the skin 

      Pavlidis, Nicholas; Klouvas, G. D.; Tsokos, M.; Bai, M. C.; Moutsopoulos, H. M. (1995)
      In this report the histopathology and the natural history of cutaneous lymphocytic vasculopathy (lymphocytic vasculitis) in patients with lymphoproliferative diseases, is described. Between January 1986 and June 1992,116 ...

    • Article  

      Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients 

      Fountzilas, George; Polichronis, A.; Katsohis, C.; Gennatas, Constantinos; Toussis, D.; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Vassilaros, S.; Semoglou, C.; Giannakakis, T.; Fahantidis, E.; Klouvas, G. D.; Tsavaris, N.; Konstantaras, C.; Makrantonakis, P.; Kolotas, C.; Zamboglou, N.; Tsiliakos, S.; Hainoglou, D.; Mylonakis, N.; Pavlidis, Nicholas (1996)
      362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD